376348-74-2

Upstream product

• 277745-50-3 methyl (3S)-3-[(tert-butoxycarbonyl)amino]-3-(3-fluorophenyl)propanoate 
• 277745-38-7 (E)-3-(3-fluorophenyl)acrylic acid tert-butyl ester 
• 277745-39-8 tert-butyl (3S,αR)-3-[N-benzyl-N-(α-methylbenzyl)amino]-3-(3'-fluorophenyl)propanoate 
• 33166-77-7 ethyl 3-(3-fluorophenyl)-3-oxopropanoate 
• 451-02-5 ethyl 3-fluorobenzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 204453-07-6 (S)-3-amino-3-(3-fluorophenyl)propionic acid ethyl ester hydrochloride 
• 528586-28-9 [(S)-1-(3-fluorophenyl)-3-hydroxypropyl]carbamic acid tert-butyl ester 
• 1220514-62-4 (S)-3-tert-butoxycfarbonylamino-3-(3-fluorophenyl)propionic acid ethyl ester 
• 500770-72-9 (S)-[1-(3-fluoro-phenyl)-3-hydroxy-propyl]-carbamic acid tert-butyl ester 

Downstream Products

• 528586-29-0 C₃₀H₄₂FN₃O₅S 
• 946488-41-1 C₂₇H₃₆FN₃O₂ 
• 1221439-88-8 C₂₅H₃₆FN₅O₂ 
• 1221188-67-5 C₂₅H₃₆FN₅O₂ 
• 1257249-89-0 C₂₉H₃₇FN₄O₂ 
• 872001-57-5 {5-[(S)-3-Amino-3-(3-fluorophenyl)-propyl]hexahydropyrrolo[3,4-c]pyrrol-2-yl}-(4,6-dimethylpyrimidin-5-yl)methanone 
• 1220514-59-9 {5-[(S)-3-Amino-3-(3-fluorophenyl)-propyl]hexahydropyrrolo[3,4-c]pyrrol-2-yl}-(4,6-dimethylpyrimidin-5-yl)methanone tartaric acid salt 
• 1220514-67-9 C₂₇H₃₄FN₅O₃ 
• 1220514-58-8 C₂₇H₃₄FN₅O₃*ClH 
• 872001-56-4 [(S)-3-[5-(4,6-Dimethylpyrimidine-5-carbonyl)hexahydropyrrolo[3,4-c]pyrrol-2-yl]-1-(3-fluorophenyl)propyl]carbamic acid tert-butyl ester 
• 612482-86-7 tert-butyl (1S)-3-[3-endo-(5-benzyl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-(3-fluorophenyl)propylcarbamate 

Relevant academic research and scientific papers

Practical asymmetric synthesis of RO5114436, a CCR5 receptor antagonist

A practical asymmetric synthesis of a 3,7-diazabicyclo[3.3.0]octane derivative (1), a representative of a new class of potent CCR5 receptor antagonists, is described. The benzylamine stereogenic center of 1 was introduced by a ruthenium-catalyzed asymmetric reductive amination using (R)-MeOBIPHEP as ligand. Aldehyde 4, prepared by Parikh-Doering oxidation, was used without workup in the reductive amination reaction, which not only simplified the process but also overcame the instability of 4. The 3,7-diazabicyclo[3.3.0]octane core was obtained by a [3 + 2] cycloaddition.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo [3.3.0] octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula (I).

IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION

The present invention provides compounds of formula (I) wherein R1 and R2 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.

N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS

The invention provides a compound of formula (I):[Chemical formula should be inserted here. Please see paper copy.] wherein R1, R2, R3, R3a, R4, R4a, R5, and R6 are as defined; or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and their use as modulators of chemokine activity (especially CCR5 activity).